Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 307Lung Neoplasms 111Pancreatic Neoplasms 70Neoplasms 56Neoplasm Metastasis 32Brain Neoplasms 31Head and Neck Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Glioblastoma 24Adenocarcinoma of Lung 23Gliosarcoma 22Non-Squamous Non-Small Cell Lung Cancer 21Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Adenocarcinoma, Bronchiolo-Alveolar 16Rectal Neoplasms 13Colonic Neoplasms 13Carcinoma, Renal Cell 13Glioma 12Esophageal Neoplasms 11Astrocytoma 11Central Nervous System Neoplasms 9Carcinoma, Squamous Cell 9Salivary Gland Neoplasms 8Prostatic Neoplasms 8Oligodendroglioma 8Gallbladder Neoplasms 8Adenocarcinoma 8Ovarian Neoplasms 7

Interventions

Paclitaxel 3Bevacizumab 3fludarabine 2Nivolumab 2Gemcitabine 2Carboplatin 2rucaparib 1pembrolizumab 1liposomal doxorubicin 1dostarlimab 1Taxes 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy 1Melphalan 1Ipilimumab 1Immunoglobulin G 1Erlotinib Hydrochloride 1Doxorubicin 1Docetaxel 1Disulfides 1Dexamethasone 1Celecoxib 1Capecitabine 1Busulfan 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Clear Cell × Erlotinib Hydrochloride × Clear all
NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 11 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡